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Editorial
The ethics of practice
In an institutional environment, significant controls 
are applied to the conduct of research and researchers 
who wish to investigate issues that require human or 
animal use. Scrutinising ethics committees oversee and 
sanction all applications to safeguard and preserve the 
health and safety of participants. The procedure for 
acquiring ethics approval is sometimes an agonising 
process to ensure that all adverse possibilities are 
considered and human participants have a right of 
redress and procedural pathways to follow should 
misadventure or offence occur. Laboratory animals 
are not quite so fortunate but must be managed in a 
caring and pain-free manner.
Is this so in private clinical practice? Patients are 
advised of treatment options, outcomes and possible 
adverse effects before a decision to proceed is made. 
They are required to sign an informed consent 
document but are they really informed to a level of 
full understanding such that they become responsible 
for their decisions? With exceptions, patients are 
undergoing orthodontic treatment for the first time 
and have no concept of expectations except for the 
largely positive information provided by the clinician 
and the likely negative accounts delivered by their 
peers. 
In these circumstances, patient ignorance can be 
a blessing. Patients may be blissfully unaware that 
the procedure being conducted on them is being 
performed for the first time, the appliance being 
inserted is largely untested, the magical bracket is 
unproven as is the new arch wire material. Do we not 
try things out on our patients to see what happens, in 
the expectation that the right option has been made? 
After all, there is only the assurance from a supply 
company that all will be well.
This system of trial and error would not survive in an 
institutional environment in which hospitals are fearful 
of medico-legal consequences. All procedures and new 
materials are required to be passed through evaluation 
committees with supporting documentation attesting 
to the safety of the product. In the majority of 
instances safety assurance cannot be provided. No 
longer can new materials be trialled on institutional 
patients. A recent example of rejection was the free 
supply of a new aligner material that could not be 
accepted because it did not fulfil occupational health 
and safety requirements. A new nickel-chromium wire 
was also denied use for the same reason. It is then with 
trepidation that research clinical trials are entertained 
because the administration involved to gain approval 
and acceptance is overwhelming and can be denied by 
a simple typographical error!
On one hand there is the rigidity of a government/
institutional/hospital system and, on the other, 
the freedom of private practice experimentation. 
It could be true that new products and procedures 
are developed and are trialled for efficacy by private 
clinicians to determine outcome. Surely there is 
an ethical dilemma in this practice that needs to be 
considered. After all, the patient’s best interest and 
health and welfare remain uppermost.
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